A prospective follow-up on neonatal health following controlled ovarian stimulation with follitropin delta or follitropin alfa

Havelock, Jon; Claman, Paul; Martín, Fernando Sánchez; Göthberg, Marie; Andersen, Eva; Mannaerts, Bernadette

doi:10.1016/j.fertnstert.2018.07.577

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We encountered only three cases when the procedure needed to be stopped ( n = 2 were non-responders and n = 1 exhibited moderate adverse reactions). Even though the number of volunteers is not comparable with that of Martin and co-authors [ 12 ], the number of follicles, oocytes, and embryos was higher in women under 35 years compared with those over 35 years even though the groups were unequal; n = 1719–95% CI 1.46, n = 1279–95% CI 1.17, and n = 677–95% CI 0.92 and n = 814–95% CI 1.54, n = 612–95% CI 1.22, and n = 301–95% CI 0.83.…”

Section: Discussionmentioning

confidence: 88%

Follitropin Delta as a State-of-the-Art Incorporated Companion for Assisted Reproductive Procedures: A Two Year Observational Study

et al. 2021

View full text Add to dashboard Cite

Background and objectives: The latest reports suggest that follitropin delta is a highly efficient recombinant human follicle-stimulating hormone (r-hFSH) that became a part of the current assisted reproductive technologies (ARTs). Therefore, the present study aims to assess a series of parameters (follicles, oocytes, and embryos) and further by the outcomes in women following the administration of follitropin delta. Materials and methods: This observational study included 205 women. They were aged between 21 and 43 years (mean 33.45) and an anti-Müllerian hormone (AMH) level ranging from 0.11 to 16.00 ng/dL (mean 2.89). Results: In accordance with the established methodology and following the centralization of data, a total of fifty-eight pregnancies (28.29%) were achieved; forty-five (36.88%) were achieved in women under 35 years and thirteen (15.66%) in women above 35 years. These figures are positively correlated with women’s age considering that the number of follicles >18 mm, oocytes fertilized and embryo(s) varies among groups. Regarding the interest parameters, we noted n = 1719 follicles > 18 mm, n = 1279 retrieved oocytes, and n = 677 embryos at day 3. On the other hand, the following figures have been registered in women above 35 years: 814—follicles > 18 mm, 612 oocytes retrieved and 301 embryos at day 3. During this study, we registered only three cases of abortions (n = 1—0.81% in women under 35 years and n = 2—2.40% in women above 35 years). Nine pregnancies (7.37%) were stopped from evolution in females under 35 years, and twelve pregnancies (n = 8—6.55% in women under 35 years, while n = 4 in women above 35 years) were unsuccessful. A twin pregnancy has been confirmed (1.20%) in women above 35 years, six ongoing pregnancies (4.91%) in those under 35 years, and two in both groups (one per group—n = 1—0.81%, and 1.20%—n = 1) in which we did not know the exact result were registered at the end of the established studied interval. However, there were also situations in which the treatment cause an over-reactivity or had no effect; n = 2 were non-responders, and n = 1 exhibited moderate ovarian hyperstimulation syndrome (OHSS). Conclusions: Based on our results, we strongly encourage the use of this recombinant gonadotropin on a much larger scale.

show abstract

Section: Discussionmentioning

confidence: 88%